Alicia Jackson, the director of the Advanced Research Projects Agency for Health (ARPA-H), has been placed on administrative leave following reports that she publicly endorsed a federal policy change on menopause hormone therapy while holding significant financial stakes in a company that could benefit from that shift. Jackson, who leads the agency responsible for investing taxpayer funds in medical technology, appeared at a Department of Health and Human Services (HHS) press conference last November to support the removal of “black box” warnings on hormone replacement therapies. Financial disclosure records indicate she retained at least $115,000 in stock of Evernow, an online platform connecting women with menopause specialists, which she founded and previously led as CEO.
What the Right Is Saying
Conservative voices and media outlets have highlighted the potential for regulatory capture and the mismanagement of federal appointments under the current administration. The focus has been on the lack of transparency regarding Jackson’s role in the policy decision and the subsequent administrative action taken by HHS. Bloomberg Law reported on a draft memo from an agency official that sought to grant Jackson a conflict waiver covering 30 investments, though Evernow was not explicitly listed in that draft. This omission has fueled arguments that the vetting process for high-level appointees with entrepreneurial backgrounds is inadequate.
Supporters of the policy change, including many in the health-tech sector, argue that removing the black box warning was a necessary scientific correction to reverse nearly two decades of stigma surrounding menopause treatment. They contend that Jackson’s advocacy aligned with broader Republican efforts to reduce regulatory burdens on medical innovations and improve women’s health outcomes. However, the specific controversy centers on whether her financial interests clouded her judgment or influenced the agency’s public messaging, rather than the scientific merit of the policy itself.
What the Left Is Saying
Ethics experts and progressive commentators argue that Jackson’s actions represent a clear conflict of interest that undermines public trust in federal health agencies. Virginia Canter, a former White House ethics lawyer who served under four presidents, described Jackson’s endorsement of the warning removal as “alarming” and an “obvious conflict of interest.” Canter stated, “We should care because her company is apparently intending to profit off this change in policy that she endorsed as a government official while still retaining a financial interest in the company.” She added that Jackson’s participation “puts her within the zone of a potential violation” of federal ethics laws, which prohibit employees from personally and substantially participating in matters affecting their personal finances.
Critics point to the timing of the policy shift and Jackson’s continued financial ties as evidence of insufficient ethical safeguards. Although the Food and Drug Administration’s expert panel had recommended ending the warning requirement months before Jackson joined the government, her active public role in promoting the HHS decision while holding equity in a related venture has drawn scrutiny. ProPublica reported that Jackson’s financial disclosures, filed in October and two months ago, remain uncertified, a step that ethics experts note often precedes inspector general investigations when compliance cannot be confirmed.
What the Numbers Show
Financial disclosure records obtained by ProPublica indicate that Jackson holds at least $115,000 in Evernow stock, along with an unknown amount of stock options. She and her husband, a venture capitalist, maintain a multimillion-dollar portfolio that includes 30 investments requiring recusal or waiver considerations. The policy in question involved the elimination of “black box” warnings, the most severe type of federal safety label, for hormone replacement therapies. Months after the policy announcement, Evernow launched a nationwide expansion, a move that could increase the value of Jackson’s holdings.
Jackson did not respond to detailed questions from ProPublica over a two-month period, and HHS declined to answer additional questions about the timing of her leave or the scope of any ongoing investigations. The agency confirmed her placement on administrative leave in a statement last week, noting it would “assess the facts before determining any change in her status.” The FDA’s advisory panel had recommended the removal of the warnings prior to Jackson’s arrival in government, suggesting the scientific groundwork was laid independently of her tenure, though her public endorsement occurred while she was an active official.
The Bottom Line
The case underscores the complex ethical challenges faced by the Trump administration as it appoints business leaders and entrepreneurs to key regulatory roles. With Jackson on administrative leave, the HHS inspector general’s potential involvement could set a precedent for how financial conflicts are handled when officials publicly advocate for policies that benefit their personal investments. The situation also raises questions about the adequacy of existing disclosure and recusal mechanisms in agencies like ARPA-H, which manage substantial federal grants in the health sector. Further developments will depend on the outcome of the internal assessment and whether certification of Jackson’s financial disclosures can be resolved.